chemo- therapy; negativea or positive) Treatment regimen (bevacizumab or othersa) OS Age (< 65a or ≥ 65 years) Sex (femalea or male) ECOG PS (0 or 1, 2) Primary tumor location (lefta or right) Single organ pulmonary metastases (negativea ...
In a further aspect, a method is disclosed for aiding in the treatment of or for treating an esophageal cancer patient selected for a second round of a therapy comprising administration of an effective amount of a platinum drug prior to operative therapy, based on an intratumoral ERCC1 gene ex...
Systemic chemo was FOLFOX in 3 cases and FLOT in 2, while the number of PIPAC procedures was 2 in 2 patients and 1 in the remaining cases. All patients underwent total gastrectomy with D2 lymphadenectomy and HIPEC was added in 3 cases. R0 was achieved in 4 patients; the remaining one ...
Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses. Molecular targeting therapy presents an opportunity to impede tumor through
One patient with CLDN18.2-overexpressing gastric signet ring cell carcinoma who progressed on multiple lines of chemotherapies and anti-PD1 and anti-VEGF therapies in the 6 mg/kg cohort achieved a confirmed partial response at week 12. These results demonstrated that TST001 had a manageable ...
We think that clinical research with IDH-inhibitors should not focus on monotherapy in chemo-refractory disease, but in our opinion, a more challenging setting will be their early use in combination with chemotherapy or other targeted therapies. As an example, preclinical studies showed that IDH ...
chemo- therapy; negativea or positive) Treatment regimen (bevacizumab or othersa) OS Age (< 65a or ≥ 65 years) Sex (femalea or male) ECOG PS (0 or 1, 2) Primary tumor location (lefta or right) Single organ pulmonary metastases (negativea ...